Psoriasiform eruption induced by infliximab.
OBJECTIVE
To report a case of psoriasiform eruption induced by infliximab.


METHODS
A 46-year-old woman with enterocutaneous fistula secondary to Crohn's disease developed pruriginous, erythematous, desquamative plaques on her elbows, knees, hands, and buttocks after receiving the second and third doses of intravenous infliximab. Histologic examination showed a lichenoid pattern. No new cutaneous lesions appeared after cessation of infliximab therapy.


CONCLUSIONS
Several cutaneous reactions secondary to infliximab, a monoclonal antibody against tumor necrosis factor-alfa, have been described. Psoriasiform dermatitis has not been reported as a cutaneous reaction to infliximab, but there have been several previous reports of psoriasiform dermatitis secondary to other drugs. An objective causality assessment revealed that the adverse event was probable.


CONCLUSIONS
This is the first report of a clinico-pathologic dissociated pattern of cutaneous reaction showing a histopathologic picture of lichenoid dermatitis resulting from infliximab treatment.
Verea
María M
MM
Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain. der@canalejo.org
Del Pozo
Jesús
J
Yebra-Pimentel
M Teresa
MT
Porta
Angeles
A
Fonseca
Eduardo
E
D000287:Administration, Topical; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D003424:Crohn Disease / Q000150:complications / Q000473:pathology; D003875:Drug Eruptions / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006229:Hand Dermatoses / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D006801:Humans; D000069285:Infliximab; D007275:Injections, Intravenous; D007412:Intestinal Fistula / Q000150:complications / Q000473:pathology; D017512:Lichenoid Eruptions / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced* / Q000150:complications* / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D000077555:Methylprednisolone Acetate; D000069285:Infliximab; D008775:Methylprednisolone